Premium Nahrungsergänzungsmittel | artgerecht

Tertiary Hyperparathyroidism – Causes and Treatment

Tertiary hyperparathyroidism is a condition in which the parathyroid glands produce excess parathyroid hormone autonomously, even after the underlying cause has been treated. It most commonly develops after long-standing chronic kidney disease.

Regular tips about health Regular tips about health

Things worth knowing about "Tertiary Hyperparathyroidism"

Tertiary hyperparathyroidism is a condition in which the parathyroid glands produce excess parathyroid hormone autonomously, even after the underlying cause has been treated. It most commonly develops after long-standing chronic kidney disease.

What Is Tertiary Hyperparathyroidism?

Tertiary hyperparathyroidism (tertiary HPT) is a disorder of the parathyroid glands in which they continuously and uncontrollably secrete excessive amounts of parathyroid hormone (PTH), even after the original triggering condition – most commonly chronic kidney disease – has been treated or resolved. Unlike secondary hyperparathyroidism, where PTH overproduction is a compensatory response to an external stimulus, in tertiary HPT the parathyroid glands have lost their ability to regulate PTH secretion. They function autonomously and can no longer appropriately control calcium levels in the blood.

Causes

Tertiary hyperparathyroidism typically develops as a consequence of prolonged secondary hyperparathyroidism. The most common causes include:

Chronic kidney disease (CKD): The most frequent underlying cause. Impaired kidney function leads to reduced production of active vitamin D and inadequate phosphate excretion, resulting in a sustained stimulus for PTH secretion.
Kidney transplantation: Even after a successful kidney transplant, previously autonomous parathyroid glands may continue to overproduce PTH.
Long-standing malabsorption syndromes: Conditions such as Crohn's disease or celiac disease can, over many years, contribute to the development of tertiary HPT.

The persistent stimulation leads to hyperplasia (enlargement) of the parathyroid glands, which eventually develop autonomous, unregulated PTH production.

Symptoms

The symptoms of tertiary HPT are primarily caused by persistently elevated blood calcium levels (hypercalcemia) and the effects of excess PTH on bone:

Bone pain and increased fragility (osteitis fibrosa cystica)
Kidney stones (nephrolithiasis) and kidney calcification (nephrocalcinosis)
Muscle weakness and general fatigue
Nausea, vomiting, and loss of appetite
Neuropsychiatric symptoms such as difficulty concentrating, mood swings, or depressive episodes
Cardiac arrhythmias due to elevated calcium levels
Calcifications in soft tissues and blood vessels

Diagnosis

The diagnosis of tertiary hyperparathyroidism is based on a combination of laboratory findings and imaging studies:

Laboratory Tests

Persistently elevated parathyroid hormone (PTH) in the blood
Elevated serum calcium (hypercalcemia)
Abnormal phosphate levels in the blood
Assessment of vitamin D (25-OH vitamin D) levels
Kidney function markers (creatinine, GFR)

Imaging

Ultrasound of the parathyroid glands to identify enlargement
Sestamibi scintigraphy (parathyroid scan) for precise localization of affected glands
4D-CT or MRI for detailed preoperative imaging
Bone density measurement (DXA scan) to assess the extent of bone involvement

Treatment

Because tertiary HPT is characterized by autonomous, unregulated PTH production, medical therapies are often insufficient on their own. Surgical intervention is the treatment of choice in most cases.

Surgical Treatment (Parathyroidectomy)

Parathyroidectomy – the surgical removal of the overactive parathyroid glands – is the standard treatment. Depending on the clinical findings, either a subtotal parathyroidectomy (removal of 3.5 of the 4 glands) or a total parathyroidectomy with autotransplantation of parathyroid tissue is performed. The goal is to permanently stop PTH overproduction and normalize calcium levels.

Medical Treatment

In cases where surgery is not feasible, or as a bridging therapy, the following medications may be used:

Calcimimetics (e.g., cinacalcet): These agents increase the sensitivity of calcium-sensing receptors in the parathyroid glands and can reduce PTH secretion.
Vitamin D analogues (e.g., paricalcitol, calcitriol): Can suppress PTH production, though they are often less effective in tertiary HPT.
Phosphate binders to help control phosphate levels.

Follow-Up Care

After surgery, regular monitoring of calcium, phosphate, and PTH levels is essential. Temporary calcium and vitamin D supplementation is frequently required, as the remaining gland tissue may initially have reduced function – a condition known as hungry bone syndrome.

References

Bilezikian J.P. et al. - Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism, Journal of Clinical Endocrinology and Metabolism, 2022.
KDIGO (Kidney Disease: Improving Global Outcomes) - Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD), 2017.
Longo D.L. et al. - Harrison's Principles of Internal Medicine, 21st Edition, McGraw-Hill, 2022.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.

Most read entries

3 Posts in this encyclopedia category